Prolonging Ticagrelor Beyond a Year of Acute Coronary Syndrome: Worth or Harmful?

Author(s): Daniel Aradi*, Dome Dezsi, Gabor Veress, Bela Merkely.

Journal Name: Current Vascular Pharmacology

Volume 16 , Issue 5 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Platelet activation plays a central role in triggering and complicating acute coronary syndromes, especially in case of stent thrombosis and myocardial infarction. On top of aspirin, P2Y12- inhibitors are successfully used to treat and prevent these events for a duration of one year after an acute coronary episode or 6 months after drug-eluting stent implantation. However, patients with acute coronary syndromes remain at heightened risk for recurrent ischemic events after the recommended durations of P2Y12-inhibitors and therefore, prolonging treatment is often considered in clinical practice. However, the higher risk for bleeding limits the utility of such approach to a restricted group who is still poorly defined by available measures. This review aims to discuss potential benefits and highlight important pitfalls of prolonged treatment with P2Y12-inhibitors, with a focus on ticagrelor, an attractive reversible P2Y12-inhibitor in patients after myocardial infarction.

Keywords: Bleeding, clopidogrel, late outcomes, PCI, prasugrel, thrombosis, ticagrelor.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [446 - 450]
Pages: 5
DOI: 10.2174/1570161116666180117104613
Price: $65

Article Metrics

PDF: 30